Could a lower dose of this lung cancer drug be just as effective?
NCT ID NCT05037331
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This study is testing whether a lower dose of the targeted cancer drug osimertinib can safely control advanced EGFR-positive non-small cell lung cancer. About 58 adults whose cancer has not responded to surgery or radiation will take 80 mg every other day. Researchers will monitor side effects, tumor shrinkage, and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Conditions
Explore the condition pages connected to this study.